MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.

M L RealeF PassigliaF CappuzzoG MinutiM OcchipintiA BulottaA DelmonteC SiniD GalettaE RocaG PelizzariD CortinovisE GariazzoS PilottoF CitarellaE BriaP MuscolinoD PozzessereA CartaD PignataroL CalvettiF LeoneM BaniniC Di MiccoE BaldiniA FavarettoU MalapelleS NovelloG PaselloM Tiseo

Published in: ESMO open (2024)

Capmatinib and tepotinib represent an effective treatment option in NSCLC patients with METex14. Real-world efficacy outcomes are worse than those reported in prospective clinical trials. Their activity is more pronounced in the treatment-naïve population, suggesting that this is the right setting in the management of patients with METex14.

Keyphrases

clinical trial
small cell lung cancer
randomized controlled trial
emergency department
single cell
type diabetes
machine learning
metabolic syndrome
tyrosine kinase
skeletal muscle
advanced non small cell lung cancer
adverse drug
insulin resistance
artificial intelligence
replacement therapy